To Evaluate The Efficacy Of Sacubitril-valsartan In The Treatment Of Heart Failure With Reduced Ejection Fraction

Objective:To evaluate the efficacy and safety of sacubitril-valsartan in the treatment of heart failure with reduced ejection fractionMethods:Eighty patients with HFr EF admitted to the Department of Cardiovascular Medicine of the Third People’s Hospital of Hubei Province from January 2021 to December2021.The enrolled patients were divided into control group and treatment group by random number table method,all of which received basic anti-heart failure therapy.Among them,the basic treatment of heart failure mainly includes:diuretics,cardiac enhancers,aldosterone receptor antagonists,beta blockers,low sodium diet,nutritional support,etc.The treatment group was treated with Sacubitril-valsartan(initial dose of 25mg orally,BID),and the dose was doubled every 1 week until the target dose(200mg BID)or the maximum tolerated dose was reached;The control group was treated with Candesartan(initial dose of 4mg orally,QD),and the dose was also doubled every 1 week until the target dose(32mg,QD)or the maximum tolerated dose.The two groups were followed up 6 months after treatment.SBP,DBP,HR,clinical efficacy,NT-pro BNP,blood K~+,e GFR,echocardiogram results and6-MWT were recorded before treatment and 6 months after treatment,respectively,and further statistical analysis was performed.Results:1.Candesartan control group:after 6 months of treatment,blood pressure,blood NT-pro BNP,LVEF value,LVDs,LVDd,6-MWT were improved compared with before treatment,the difference was statistically significant(P<0.05)2.Sacubitril-valsartan treatment group:after 6 months of treatment,blood pressure,NT-pro BNP,LVEF,LVDs,LVDd,6-MWT were all improved compared with before treatment,with statistical significance(P<0.05)3.Comparison between Candesartan group and Sacubitril-valsartan group:Clinical efficacy,NT-pro BNP,LVEF and LVDs of Sacubitril-valsartan group were better than those of Candesartan group(P<0.05)4.All 80 patients completed the experiment;There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05),and no adverse cardiovascular events,such as malignant arrhythmia and sudden cardiac death,occurred in the two groups.Conclusion:Sacubitril-valsartan is effective and safe in the treatment of HFr EF,and can significantly improve clinical symptoms and left ventricular systolic function,with good safety.